ClinicalTrials.gg
CompletedNCT05652257Updated Mar 23, 2023

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

A Phase 1 interventional study of [14C]-brensocatib in Healthy Volunteers, sponsored by Insmed Incorporated. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-03-23.

Sponsored by Insmed Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 2 months ago, and no results have been posted to the registry.
  • Registered 1 year 3 months after the study started (first participant enrolled Aug 2021, registered Dec 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary purpose of the study is to determine the mass balance of total radioactivity and the routes of elimination by quantifying the urinary and fecal excretion of radioactivity following a single oral administration of [14C]-brensocatib, to characterize the pharmacokinetics (PK) of brensocatib in plasma and urine, PK of total radioactivity in plasma, whole blood, urine and to determine the blood-to-plasma ratios of total radioactivity.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • [14C]-brensocatib
03

In context

Lead sponsor

Insmed Incorporated is the lead sponsor of 50 studies on the registry; 8 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 8 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. between 18.0 and 32.0 kilograms per square meter (kg/m\^2), inclusive, at screening.
  2. In good health, determined by no findings from medical history, physical examination, 12-lead (ECG), vital sign measurements, and clinical laboratory evaluations (congenital nonhemolytic hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct ] is not acceptable) at screening and check-in as assessed by the investigator (or designee).

Exclusion criteria

Exclusion Criteria:

  1. Positive hepatitis panel and/or positive test. Results consistent with previous vaccination to are not exclusionary.
  2. Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing.
  3. Poor peripheral venous access.
  4. Have previously completed or withdrawn from this study or any other study investigating brensocatib, and have previously received brensocatib. Known allergy to brensocatib or any of the used in the formulation.
  5. Exposure to significant diagnostic or therapeutic radiation (e.g., serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.
  6. Participated in more than 3 radiolabeled drug studies in the last 12 months (previous study to be at least 4 months prior to check-in to the study site where exposures are known to the investigator or 6 months prior to check-in to the study site for a radiolabeled drug study where exposures are not known to the investigator).

Note: Other inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    [14C]-brensocatib

    Healthy participants will receive single oral dose of \[14C\]-brensocatib on Day 1 under fasted conditions.

    Drug: [14C]-brensocatib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Time Curve (AUC) of Brensocatib in Plasma

    Pharmacokinetics of brensocatib following a single dose in healthy participants will be assessed.

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

  2. AUC∞ Plasma Brensocatib/Plasma Total Radioactivity Ratio Calculated as AUC∞ of Plasma Brensocatib Relative to AUC∞ of Plasma Total Radioactivity

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

  3. AUC∞ Blood/Plasma Total Radioactivity Ratio Calculated as AUC∞ of Whole Blood Total Radioactivity to AUC∞ of Plasma Total Radioactivity

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

  4. Amount Excreted in Urine (Aeu) of Brensocatib

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

  5. Total Radioactivity Expressed as Amount of [14C]-brensocatib Excreted in Urine

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

  6. Total Radioactivity Expressed as Amount of [14C]-brensocatib Excreted in Feces (Aef)

    Time frame: Pre-dose and at multiple timepoints post-dose on Day 1 up to maximum Day 14

Secondary outcomes

  1. AUC of Brensocatib Metabolites in Plasma

    Pharmacokinetics of the metabolites following a single dose of brensocatib in healthy participants will be assessed.

    Time frame: Pre-dose and at multiple timepoints post-dose on Days 1 to 9

  2. Number of Participants Who Experienced at Least one Adverse Event (AE)

    Safety and tolerability of a single dose of brensocatib will be determined in healthy participants.

    Time frame: Up to Day 14

07

Study locations

1 site
  • USA001
    Madison, Wisconsin 53704, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Sep 2021, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2022
First posted
Dec 15, 2022
StartActual
Aug 13, 2021
Primary completionActual
Sep 14, 2021
CompletionActual
Sep 14, 2021
Last update
Mar 23, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05652257
Responsible party
Sponsor
First posted
Dec 15, 2022
Start date
Aug 13, 2021
Primary completion
Sep 14, 2021
Completion
Sep 14, 2021
Last update
Mar 23, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brensocatib

Start the discussion